For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.
Patients aged 18 to 75 years;
clinical diagnosis with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) ;
undergoing PCI
baseline LDL-C 1.8 mmol/L 3.4 mmol/L note: NSTE-ACS includes non-ST-elevation myocardial infarction and unstable angina.
Severe heart failure (Killip III or IV) or cardiogenic shock;
Previous hemorrhagic cerebrovascular disease history;
Uncontrolled or recurrent arrhythmic events;
poorly controlled hypertension;
China National Center for Cardiovascular Diseases
Lead sponsor
Innovent Biologics, Inc.
Collaborator